Staphylococcus aureus is a rapidly growing health threat in the U.S., with resistance to several commonly prescribed treatments. A high-throughput screen identified the antihistamine terfenadine to possess, previously unreported, antimicrobial activity against S. aureus and other Gram-positive bacteria. In an effort to repurpose this drug, structure−activity relationship studies yielded 84 terfenadine-based analogues with several modifications providing increased activity versus S. aureus and other bacterial pathogens, including Mycobacterium tuberculosis. Mechanism of action studies revealed these compounds to exert their antibacterial effects, at least in part, through inhibition of the bacterial type II topoisomerases. This scaffold suffers from hERG liabilities which were not remedied through this round of optimization; however, given the overall improvement in activity of the set, terfenadine-based analogues provide a novel structural class of antimicrobial compounds with potential for further characterization as part of the continuing process to meet the current need for new antibiotics.
■ INTRODUCTION
The ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) are responsible for 51% of all U.S. hospital-acquired infections (HAIs). 1 Among these, S. aureus accounts for 16% of HAIs and is responsible for more deaths in the U.S. annually than HIV/AIDS. 1−3 The organism's high morbidity and mortality rates are, in part, attributable to the fact that S. aureus has developed resistance to currently available antibiotics. 4 The quinolone class of antibiotics was once a predominant treatment option for S. aureus infections; 5 however, due to increasing quinolone resistance, these drugs continue to have diminishing efficacy. 6, 7 The antimicrobial activity of the quinolones and fluoroquinolones, such as ciprofloxacin ( Figure 1 ) and levofloxacin, is thought to be mediated by their ability to inhibit the DNA religation activity of the bacterial type II topoisomerases, DNA gyrase and topoisomerase IV. Resistance can arise from decreased access to these cellular targets or by mutations within the type II topoisomerases. 8, 9 Despite the rise in resistance to quinolones, their previous success validates the type II topoisomerases as valuable targets in searching for novel antimicrobial scaffolds. Indeed, academic and industrial laboratories have devoted much effort toward developing novel bacterial type II topoisomerase inhibitors (NBTIs) featuring compound scaffolds chemically distinct from those of the quinolone class of antibiotics, 10−15 including the Nlinked piperidine 6-(methyloxy)-4-(2-{4-[( [1, 3] oxathiolo [5,4c] pyridin-6-ylmethyl)amino]-1-piperidinyl}ethyl)-3-quinolinecarbonitrile dihydrochloride 43 (GSK299423). 16 However, despite NBTI development efforts, pharmaceutical pipelines are still severely lacking quality antibiotic candidates, 17 and the loss of several antibiotic groups in the pharmaceutical industry only exacerbates the problem. 18, 19 This, coupled with increasing prevalence of quinolone-resistant S. aureus, makes it paramount that novel small molecule inhibitors are discovered for type II topoisomerases for the therapeutic intervention of staphylococcal disease and possibly other bacterial pathogens.
The practice of drug repurposing, in which a drug previously developed to treat one disease is then identified for possibly treating a second disease, has emerged as an attractive alternative for drug discovery research. 20, 21 The repurposed drug most likely has already been optimized for physicochemical and pharmacokinetic properties, 22 providing a more attractive starting point as far as these factors are concerned. Recently, the National Center for Advancing Translational Science (NCATS) has invested in this area with the formation of the NIH Chemical Genomic Center Pharmaceutical Collection as both an informatics and screening resource for drug repurposing research, 23 lending credence to the potential and popularity of drug repurposing.
Given the need for novel antimicrobials and the attractive features of drug repurposing, we previously performed a highthroughput screen (HTS) to identify FDA approved drugs with bactericidal activity toward the ESKAPE pathogens. 24 Results identified a set of compounds that were developed for other indications but displayed previously unreported antimicrobial activity. One particular hit, the antihistamine terfenadine ( Figure 1 ), was found to possess antimicrobial activity versus the planktonic, biofilm, and small-colony variant forms of S. aureus. Given the activity and relatively convenient synthetic route to analogues, terfenadine provided an attractive starting point for studying the structure−activity relationship (SAR) of S. aureus antimicrobial activity. However, terfenadine is not without its flaws. The clinical use of the drug was discontinued in favor of its active metabolite fexofenadine (Allegra) because a segment of the patient population exhibited cardiac arrhythmia, attributed to prolonged QT interval, 25, 26 due to inhibition of the human ether-a-go-go related gene (hERG) potassium channel. 27 Nonetheless, it has been shown previously that it is possible to reduce hERG liabilities via an SAR strategy 13 and given the encouraging results from the HTS, we decided it would be beneficial to embark on an SAR-optimization study of terfenadine (1a) and its analogues for inhibition of S. aureus and those results are reported herein.
■ RESULTS AND DISCUSSION Chemistry. A total of 84 terfenadine-based analogues were synthesized for optimization of antimicrobial activity against S. aureus strain UAMS-1, 14 a well-studied osteomyelitis clinical isolate, by standard CLSI methods. 28 The majority of analogues were synthesized by one of two routes, while several required alternate routes or further modification. The first route employs a substitution reaction with diphenyl(piperidin-4-yl)methanol (7) and corresponding substituted chloro-phenylbutanones (8) followed by subsequent reduction of the ketone intermediate (9) yielding analogues 1a−1h and 1j−1l (Scheme 1). An alternate pathway was used to synthesize analogue 1i in which the methyl 4-(4-chlorobutanoyl)benzoate 8i was prepared according to a previously reported procedure, 29 reduced, and subjected to a Finkelstein reaction with 7 to yield the desired analogue (Scheme 2). This ester was then hydrolyzed to the corresponding carboxylic acid 1m. Compound 1n was synthesized by Suzuki−Miyaura coupling using a procedure adapted from Moseley et al. 30 (Scheme 3A). The final analogue in this set, the known metabolite of terfenadine (1p also known 31 was generated according to a previously published procedure 32 (Scheme S2 in Supporting Information).
The second route to a majority of analogues was via nucleophilic substitution in which 7 was coupled with various substituted phenyl alkyl halides or tosylates (10) yielding analogues 2a−2d, 3a−3i, 4a−4r, 4t, 4w, and 4y−4bb (Scheme 4). Benzyl bromides were not available for four desired analogues, thus reductive amination was employed for analogues 4s, 4u, 4v, and 4x with the corresponding aldehydes 11a−11d (Scheme 4). A number of analogues required further modification such as reduction of the 4-nitro group of 3i, providing the 4-amino derivative 3j followed by subsequent dimethylation, yielding the 4-dimethylamino analogue 3k (Scheme 5). Analogues 3l−3n were synthesized from 3e using the aforementioned Suzuki−Miyaura cross-coupling procedure (Scheme 3B). Saponification of methyl esters 4y− 4aa resulted in carboxylic acids 4cc−4ee. A set of fivemembered heterocycles at the 4-position were synthesized in which the 4-iodo derivative 4bb was subjected to Suzuki− Miyaura cross coupling with the corresponding boronic acids or potassium trifluoroborate salts to provide 4ff−4ii, while a copper mediated Ullman type coupling of pyrrole 33 in acetonitrile afforded the pyrrole derivative 4jj (Scheme 6).
Compounds 2e and 2f were prepared by alkylation of 7 with 3-bromopropan-1-ol, providing the alcohol intermediate 12,
which was subsequently tosylated and subjected to substitution conditions with 4-tert-butylaniline or 4-tert-butylphenol, respectively (Scheme 7). Analogue 2g was synthesized via reductive amination of 9a to arrive at the benzylic amine. Each enantiomer for terfenadine, 2h and 2i, were synthesized via a previously reported procedure (Supporting Information). 34 A slightly more polar tert-butyl isostere, methyl oxetane, 35 was prepared using an adapted procedure from Wuitschik et al. 36 The key step being a rhodium catalyzed coupling of 4-(2hydroxyethyl)phenylboronic acid with the Michael acceptor intermediate. Further modification resulted in analogue 3o (Scheme 8).
Analogues 5a and 5b ( Figure 2 ) were created by utilizing the same substitution and subsequent reduction conditions described for previous series. The diphenyl piperazine intermediate was synthesized using a previously reported procedure, 37 followed by substitution with 8a and reduction to arrive at 5c. Finally, 5d and 5e were created by reducing the alcohol of 7 in either TFA alone or in the presence of sodium borohydride. 38 The reduced intermediates were then subjected to the same substitution/reduction procedure as described for previous series (Supporting Information).
The final analogue combined favorable changes to the linker and pendant phenyl in an attempt to further enhance potency. This compound was synthesized via Mitsunobu chemistry in which the intermediate 12 was coupled with 4-phenylphenol, providing 6 (Scheme 7). 39 Design and SAR for Terfenadine Analogues. The SAR for all terfenadine analogues was studied using antimicrobial potency toward planktonic S. aureus UAMS-1 cells, as measured by minimum inhibitory concentration testing (MIC). Data from these assays helped drive iterative analogue design and synthesis. Mechanism of action studies on terfenadine were performed in parallel. The most promising analogues were carried into MIC assays testing across a spectrum of Grampositive and Gram-negative pathogens as well as M. tuberculosis. Furthermore, a common strategy for reducing hERG activity is to lower the log P of the compound, 40, 41 thus attempts at incorporating polar functional groups while optimizing for potency were undertaken with this goal in mind.
Series 1 compounds were designed to gain initial SAR information at the 4-position of the pendant phenyl (red region in Figure 1 ) of 1a while preserving the linker (Table 1) . A scan of lipophilic steric bulk showed that anti-S. aureus activity correlated with the size of the lipophilic groups (4-tert-butyl (1a) > 4-iso-propyl (1b) > 4-methyl (1c) > 4-H (1d)). A halogen scan at the para-position also displayed a similar trend (4-bromo (1g) > 4-chloro (1f) > 4-fluoro (1e)). The 4-phenyl analogue 1n further supports this observation, as it displayed a modest increase in potency (MIC to 8 μg/mL). Unfortunately, the introduction of polarity at this position resulted in loss of antimicrobial activity as observed for the 4-methoxy (1h), 4methyl carboxylate, and its corresponding carboxylic acid (1i and 1m) as well as for the primary metabolite of 1a, carboxylic acid 1p and the methyl ester precursor 1o (Table 1 ). These The second set of analogues was designed to study modifications to the linker (green region in Figure 1 ) while maintaining the 4-tert-butyl group on the pendant phenyl. Compounds 1j−1l scanned linker length while maintaining the benzylic alcohol and showed that changes to the length were tolerated and did not reduce activity (MICs = 8 and 16 μg/ mL). A study of linker length while altering the oxidation state on the benzylic carbon provided similar results. Analogues 2a− 2d all contained fully reduced benzylic carbons, scanning from four to one carbon linkers, respectively, and provided MICs = 8 μg/mL. The ketone precursor to the hit (9a) maintained activity (MIC = 8 μg/mL), while the three-carbon derivative (9l) showed a slight reduction in activity compared to 1a (MIC = 32 μg/mL). The ketone containing two-carbon and amidecontaining linkers resulted in a loss of activity, possibly due to restriction of movement for the phenyl group, at least in terms of amide linker. Further exploration of the necessity of the alcohol led to a benzylic amino derivative (2g) and the S-OH (2h) and R-OH (2i) enantiomers, all of which exhibited no change in activity compared to the hit. The final two analogues in this set replaced the benzylic carbon with nitrogen (2e) and oxygen (2f), resulting in slight increases in activity to MICs = 8 μg/mL for each. The SAR of the linker region suggests the secondary alcohol is not necessary for S. aureus antimicrobial activity while shortening the linker in some cases led to a small, yet consistent, improvement in activity.
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Given the modest success of the one-and two-carbon linkers from the previous set, the next two series further studied SAR on the pendant phenyl while utilizing shorter, more accessible linkers. The two carbon linker set provided mixed results as far as potency but maintained the trend of favoring lipophilic bulk at the 4-position ( Table 2 ). Moving the tert-butyl group around the pendent phenyl (3a and 3b, MIC = 16 μg/mL for each) was tolerated and did not alter activity significantly compared to 2c. The same was observed for bulkier derivatives as the 4bromo (3e), 4-trifluoromethyl (3f) displayed MICs = 16 μg/ mL for each, and 4-phenyl analogue 3l had an MIC = 8 μg/mL. Smaller and more polar substitutions in this set led to varying ranges of reduction in activity or a complete loss.
These trends continued in the one-carbon linker series as the 4-phenyl analogue 4g was the most active, with an MIC = 4 μg/ mL, a 4-fold increase in potency compared to the hit (Table 2) . Unfortunately, all polar modifications at the 2-, 3-, or 4positions led to a significant reduction or complete loss of S. aureus antimicrobial activity. A 4− 8-fold reduction in activity was observed for heterocycles at the para-position, as indicated by the 3-and 2-thiophene analogues 4ff and 4gg, 3-and 2-furan analogues 4hh and 4ii, and the N-linked pyrrole 4jj, compared to 4g, suggesting the slight increase in polarity for these common phenyl isosteres affect their activity.
A small set of analogues were designed to explore more global changes to the piperidinyl diphenylmethanol (blue region in Figure 1 ) side of 1a ( Figure 2 ). Analogues 5a−5d showed a complete loss of activity toward S. aureus; however, the removal of the alcohol while maintaining sp 3 character of the carbon (5e) was tolerated ( Table 3 ). This provides some evidence, however small, that future work could establish SAR trends on this side of the molecule.
In summary, there appears to be a trend in which lipophilicity may be driving the potency of this scaffold, at least in general. A scatter plot of log P vs MIC (Chart S1 in Supporting Information) displays this trend, with the average log P generally decreasing as potency decreases. However, there are a few analogues that lie outside of the trend, such as 4g, which has a lower calculated log P (estimated by ALOGPS) 42, 43 than 1a but displays a 4-fold increase in potency. Therefore, while the trend is general, there are a few instances in which functional group identity or placement still might play a role in the potency. A strong relationship was noticed at the 4-position of the pendant phenyl, with lipophilic bulk being beneficial for potency against S. aureus. Downsizing the tert-butyl group of the hit 1a resulted in a reduction of potency, however slight, on all occasions while the addition of a phenyl group in this position was the lone substitution, leading to a modest increase of potency.
The addition of hetercyclic isosteres (pyridinyl, thiophenyl, and furyl moieties) are comparable in size to the phenyl, however, contain slightly larger polar surface areas. The benefit of steric bulk in these cases may have been mostly negated due to increased polarity, however slight, ultimately resulting in an overall reduction of potency but not a complete loss. Modifications, either polar or nonpolar, to other positions of the pendant phenyl were unfavorable, leading to reduction or loss of potency. Therefore, SAR on the pendant phenyl, while relatively steep for the ortho-and meta-positions, did offer some room for improvement at the para-position as far as potency against S. aureus is concerned. However, further optimization to the piperidinyl diphenylmethanol side of 1a may be required for reduction of log P while maintaining or improving potency. Several modifications to the linker region provided a slight increase in potency. The benzylic alcohol was not necessary for activity, as indicated by the removal of the hydroxy group, leading to moderately increased antimicrobial potency across the four different linker lengths (2a−2d). It was also shown that substituting an amine for the alcohol or resolving the enantiomers had no effect on activity. Furthermore, substituting the benzylic carbon for an amine or ether linkage resulted in a 2-fold increase in activity compared to the hit. Given these data, it was evident that modifications to the linker could lead to an analogue with enhanced activity.
A final analogue was designed to combine the favorable ether linker modification from 2f and the 4-phenyl substitution on the pendant group to yield 6. The combination of these modifications resulted in a synergistic boost in potency, with an MIC = 1 μg/mL against S. aureus comparable to an MIC = 0.5 μg/mL for the widely prescribed fluoroquinoline, ciprofloxacin, in the same assay ( Figure 3 ). The success of the combined modifications offers optimism that more potent analogues may be within reach with future SAR studies. However, compound 
a Analogue 3h employs a pendant 3-pyridine in place of the pendant phenyl. 
>256 5e 8 Figure 3 . MIC values for ciprofloxacin, 4g, and 6. properties such as solubility and log P remain an issue and will be addressed with future work. Mechanism of Action. Transcription profiling was used to compare the cellular response of S. aureus strain UAMS-1 following challenge with a subinhibitory concentration (0.5× MIC) of terfenadine with that of cells treated with 0.5× MIC of the known topoisomerase II inhibitor, ciprofloxacin, or antibiotics with independent mechanisms of action. Results ( Figure S1 in Supporting Information) revealed that terfenadine-treated cells elicit a cellular response most similar to that of ciprofloxacin and cells treated with the DNA damaging agent mitomycin C in comparison to cells treated with subinhibitory concentrations of cell wall active agents, RNA synthesis inhibitors, or general stress responses such as cold-shock conditions and metal depletion. For instance, 221 (43%) of the 509 genes that were differentially expressed within ciprofloxacin treated cells were also differentially expressed within terfenadine-treated cells. A total of 149 (67%) of these 221 genes were also differentially expressed within mitomycin treated cells, but none of the other stress conditions evaluated. Of direct relevance to this work, while the majority of these genes (55%) are annotated as hypothetical proteins, two key components of the organism's SOS response, lexA and umuC, as well as 12 phage-associated replication proteins, were identified and known to be responsive to the topoisomerase inhibitor, ciprofloxacin. 44, 45 The similarities between the cellular response of terfenadine-, ciprofloxacin-, and mitomycin-challenged cells provided an initial indication that the scaffold's antimicrobial activity may be mediated via topoisomerase II inactivation.
As a direct test of whether the antimicrobial properties of terfenadine correlate with type II topoisomerase inhibition, S. aureus DNA gyrase and topoisomerase IV inhibition assays were used to measure each enzyme's activity in the absence and presence of various concentrations of terfenadine. As shown in Figure 4A (lanes 1 and 2), the addition of 0.5 units (U) of S. aureus DNA gyrase catalyzed supercoiling of relaxed circular plasmid pBR322 DNA, resulting in increased substrate mobility in an agarose gel, confirming that the assay conditions were appropriate to measure gyrase activity. Similar assays in the presence of increasing concentrations of terfenadine (62.5, 125, 250, and 500 μM), demonstrated that the compound was a relatively mild inhibitor of S. aureus gyrase with an apparent IC 50 value of 190 μM. Similarly, terfenadine appeared to exhibit moderate topoisomerase IV inhibitory activity ( Figure 5A ).
While these values are admittedly modest, they are comparable to the topoisomerase II inhibitor, ciprofloxacin, in these assays, which displayed IC 50 values of 110 and 4 μM for S. aureus DNA gyrase and topoisomerase IV, respectively (data not shown). This, combined with the fact that 1a did not appear to affect the activity of other enzymes assessed (S. aureus RNase J2 and RnpA; data not shown), supports the hypothesis that the compound's antimicrobial activity may, in part, correspond to its topoisomerase II inhibitory activity.
Accordingly, IC 50 values were measured for the first 48 analogues synthesized (Table 4 ) to determine whether improvements to the compound's antimicrobial activity tracked with enhanced enzyme inhibition. Results of those studies revealed two overarching features of the analogue series. First, most compounds (11 of 12 in total) displaying modest improvement in antimicrobial activity (MIC ≤ 8 μg/mL), in comparison to terfenadine, also exhibited at least modest improvement in potency toward S. aureus DNA gyrase and/or topoisomerase IV. Second, most compounds exhibiting reduced antimicrobial activity (MIC ≥ 32 μg/mL) displayed decreased potency toward the enzymes. Compounds 4g and 6, which exhibited the most improved antimicrobial properties toward S. aureus (MIC values of 4 and 1 μg/mL, respectively), also displayed modest improvements toward S. aureus DNA gyrase inhibition (IC 50 s = 130 and 50 μM, respectively) when compared to 1a. Indeed, as shown in Figure 4B , when tested at 100 μM, 4g, 6, and ciprofloxacin, all displayed improved inhibition of S. aureus DNA gyrase supercoiling activity, in comparison to the parent molecule, terfenadine. This suggests that even if the gains in potency for 4g and 6 over terfenadine are modest, they do appear to display a real improvement in DNA gyrase inhibition. Moreover, both derivatives maintained S. aureus topoisomerase IV inhibition activity that approximated the inhibitory activity of that of the parent molecule, 1a ( Figure  5B ).
Even though the terfenadine scaffold seems to be inhibiting the type II topoisomerases, it appears there may be other mechanisms contributing to the overall bactericidal effect. It is well noted that receptor promiscuity is correlated with lipophilicity. 46 Therefore, it is not out of the question that these compounds could be binding to multiple targets, and the combined effect of these targets may be exerting the antibacterial effect. Analogues 2g, 2i, 3d, 3e, and 3n all are shown to have activity versus S. aureus, with MICs ranging from 16−32 μg/mL. However, these analogues possess reduced or no activity in the DNA gyrase and topoisomerase IV assays. Therefore, they must be exerting an antimicrobial effect via other means, supporting the multiple target hypothesis. Moreover, attempts to isolate resistant strains of S. aureus provided no stable resistant organisms, also supporting a multiple target hypothesis. It should be noted that given the above correlations, expense, and laborious nature of the enzyme assays and the fact that no improvements in antimicrobial activity (≥32 μg/mL) were observed for the remaining compounds synthesized, their IC 50 values were not measured. DNA Gyrase Modeling Studies. As was shown in the previous section, the terfenadine-based scaffolds are likely to, at least in part, exert their antibacterial effect via inhibition of the type II topoisomerases. Recently, NBTIs such as 43 have been reported. 16 These NBTIs also feature a piperidine, with aromatic regions linked to the N-and 4-position. Therefore, we hypothesized that the terfenadine-based analogues may be binding in the same region as 43. A docking study was carried out using the software Surflex module of SYBYL from Certara. The receptor protein (PDB ID 2XCS) was prepared by removing the ligand, 43, and taking the corresponding ligand binding pocket defined as a 20 Å sphere around the GSK ligand. Out of 30 poses, the best pose was selected on the basis of Combined CScore (ChemScore, G_Score, D_Score, and PMF_Score), and the scores were 8.85 for 43, 7.65 for 6, and 5.99 for 1a, respectively. The scores generally correlated with the experimentally determined DNA gyrase activity (43 = 14 nM, 6 = 50 μM, and 1a = 190 μM, respectively).
To assess the potential of the terfenadine analogues for binding to other known sites on DNA gyrase, the same docking study was performed with a solved structure of ciprofloxacin (PDB ID 2XCT), 16 and the docking score of the best poses for 43 and 6 were 2.22 and 0.72, respectively. The same modeling was performed at the ATP site on the GyrB subunit, in which a pyrrolamide ligand was extracted from the ATP-binding site in a structure published by Eakin et al. 47 (PDB ID 3U2K). Both 43 and 6 were docked and provided similar docking scores (5.05 and 5.23, respectively). These in silico results suggest a higher likelihood of the terfenadine-based analogues interacting in the same region as 43 than in the other two known inhibitor binding sites.
Information from the above modeling of the binding site suggests that the aromatic character of the pendant biphenyl moiety intercalates between DNA base pairs similar to 43 ( Figure 6A ). However, due to the length of the linker, the diphenyl methanol portion may be able to interact with a section of the protein surface adjacent to the pocket in which the oxathiolo-pyridine group of 43 binds. The best pose of 6 suggests that hydrogen bonds may form between the alcohol with an acceptor phosphate group in the DNA backbone and a donor Arg1122, respectively, with additional potential hydrophobic π−π stacking interactions ( Figure 6B ). While the modeling suggests a similar binding site, further work is needed to validate these results. Future plans include designing analogues to interrogate these possible interactions, competition assays with known inhibitors, and solving a terfenadinebased ligand bound DNA gyrase structure aimed at providing more definitive evidence as to the binding site for this scaffold.
Antimicrobial Spectrum of Activity of Terfenadine, 4g, and 6. As stated above, terfenadine (1a) was found to have antistaphylococcal activity in a HTS campaign using the S. aureus strain UAMS-1, a methicillin-susceptible strain. To determine the spectrum of antimicrobial activity for 1a, the activity of the scaffold toward genetically diverse S. aureus strains, other Gram-positive and Gram-negative bacterial species of immediate healthcare concern, and Mycobacterium tuberculosis was determined. As shown in Table 5 Neither 1a nor its analogues were active against wild-type Gram-negative species tested thus far. The MIC is >256 μg/mL for both K. pneumoniae CKP4 and E. coli 8314. The MIC value for A. baumannii 98-37-09 is 256 μg/mL. However, when tested versus a membrane-compromised, efflux pump-deficient strain of E. coli (tolC, imp), all three compounds did show activity. Therefore, the lack of efficacy versus Gram-negative species may be due to an inability of these compounds to traverse the outer membrane to gain entry to the cellular target and/or a result of expulsion via efflux pumps. Nonetheless, these results indicate that a terfenadine scaffold could potentially be optimized for use as an antimicrobial against Gram-positive organisms and potentially Gram-negative organisms if treated with an efflux pump inhibitor.
hERG Activity of Terfenadine Analogues. Compounds 4g and 6 emerged as the most promising analogues with MICs = 4 and 1 μg/mL, respectively, against S. aureus. Unfortunately, the SAR did not allow for addition of polar functionality, and the predicted log P for each compound remains relatively high when compared to the hit. The predicted log P values for 1a, 4g, and 6 are 5.89, 5.73, and 6.30, respectively (estimated by ALOGPS). Therefore, it appears no improvement was able to be gained in log P while optimizing for potency in this set of analogues. This observation carries over to the measured hERG activity for each compound. Terfenadine (1a) displayed a hERG IC 50 = 130 nM, while analogues 4g and 6 display hERG IC 50 s = 210 and 140 nM, respectively. While hERG activity was not able to be reduced during this campaign, future SAR work on the piperdinyl diphenylmethanol side of the molecule may still provide opportunities for addition of polarity or reduction of the pK a of the molecule, thus reducing log P and potentially reducing hERG activity.
■ CONCLUSIONS
The project commenced with a phenotypic whole-cell HTS against the ESKAPE pathogens using a library of off-patent FDA-approved drugs. The HTS identified the antihistamine, terfenadine (1a), as a hit possessing previously unreported antimicrobial activity versus S. aureus (MIC = 16 μg/mL). In an effort to repurpose 1a, a total of 84 terfenadine-based analogues were designed and synthesized for optimized antimicrobial activity versus S. aureus. Analogues 4g and 6 displayed improved activity (4 and 1 μg/mL respectively) compared to 1a and promising activity toward other bacterial pathogens of immediate healthcare concern. The SAR study revealed bulky lipophilic substituents at the 4-position of the pendant phenyl, shortening the linker and/or replacing the benzylic carbon with oxygen, enhance activity. Mechanism of action studies suggest 1a, 4g, and 6 are likely acting as bacterial type II topoisomerase inhibitors targeting both DNA gyrase and topoisomerase IV. However, there is evidence to suggest this scaffold may have multiple targets. Docking studies show these analogues may bind within the same site as the NBTI 43. While antimicrobial activity versus S. aureus strains tested, including fluoroquinolone, methicillin and vancomycin resistant isolates, and M. tuberculosis was improved, the hERG liability and physicochemical properties for this class of compounds still remains an issue. We believe 6, and possibly 4g, provide good starting points for further optimization to the piperidinyl diphenylmethanol side of the molecule. Furthemore, a strategy has been devised to improve antimicrobial activity while reducing hERG activity. In future work, we also plan to confirm the possible DNA gyrase binding site for these analogues via competition assays and crystallography studies.
■ EXPERIMENTAL SECTION
Chemistry: General Experimental. Purity of all final compounds was confirmed by HPLC/MS analysis, and all compounds have a final purity of ≥95% purity. 1 H and 13 C NMR spectra were recorded on a Bruker AM 400 spectrometer (operating at 400 and 101 MHz, respectively) or a Bruker AVIII spectrometer (operating at 500 and 126 MHz, respectively) in CDCl 3 with 0.03% TMS as an internal standard or DMSO-d 6 . The chemical shifts (d) reported are given in parts per million (ppm), and the coupling constants (J) are in hertz (Hz) . The spin multiplicities are reported as s = singlet, bs = broad singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublet, and m = multiplet. The LCMS analysis was performed on an Agilent 1200 RRL chromatograph with photodiode array UV detection and an Agilent 6224 TOF mass spectrometer. The chromatographic method utilized the following parameters: a Waters Acquity BEH C-18 2.1 mm × 50 mm, 1.7 mm column; UV detection wavelength = 214 nm; flow rate = 0.4 mL/min; gradient = 5−100% acetonitrile over 3 min with a hold of 0.8 min at 100% acetonitrile; the aqueous mobile phase contained 0.15% ammonium hydroxide (v/v). The mass spectrometer utilized the following parameters: an Agilent multimode source which simultaneously acquires ESI+/APCI+, a reference mass solution consisting of purine and hexakis(1H,1H,3H-tetrafluoropropoxy) phosphazine, and a makeup solvent of 90:10:0.1 MeOH:water:formic acid which was introduced to the LC flow prior to the source to assist ionization.
General Method A. 1-(4-(tert-Butyl)phenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-one (9a). To a vial was added diphenyl(piperidin-4-yl)methanol 7 (1.19 g, 4.45 mmol), 1-(4-(tert-butyl)phenyl)-4-chlorobutan-1-one 8a (1.01 g, 4.24 mmol), and sodium bicarbonate (0.42 g, 5.09 mmol) with water and 2butanone (18 mL, 1:5). The reaction stirred at 85°C for 16 h and was then allowed to cooled to rt and diluted with water (50 mL). The reaction was diluted with water (20 mL) and extracted with EtOAc (3 × 50 mL). The organic layers were combined then dried with MgSO 4 , filtered, concentrated, and purified by MPLC (0−10% MeOH:CH 2 Cl 2 ) to produce pure 9a (1.37 g, 2.92 mmol, 69% yield) as a colorless oil. 1 General Method B. 1-(4-(tert-Butyl)phenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-ol (1a). To a vial was added 9a (0.20 g, 0.422 mmol) and MeOH (2 mL). The sodium borohydride (0.032 g, 0.844 mmol) was then added and the reaction stirred at rt for 3 h. The reaction was concentrated, water (5 mL) was added, and a white precipitate formed. The precipitate was filtered out and then dissolved in CH 2 Cl 2 (10 mL), dried with MgSO 4 , filtered, and concentrated to produce pure 1a (0.15 g, 0.320 mmol, 76% yield) as on oil. 1 1-([1,1′ -Biphenyl]-4-ylmethyl)piperidin-4yl)diphenylmethanol (4g). To a vial was added the 4-phenylbenzyl bromide 10t (0.10 g, 0.40 mmol), 7 (0.098 g, 0.37 mmol), and acetonitrile (3 mL). The triethylamine (0.077 mL, 0.55 mmol) was added and the reaction stirred at 70°C for 4 h. The reaction was cooled to rt and diluted with water then extracted with EtOAc. The EtOAc layer was concentrated, and the crude product was purified by reverse-phase MPLC (10−100% MeCN:water) to produce the pure 4g (0.12 g, 0.27 mmol, 72% yield). 1 1-Phenyl-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-one (9d). Method A: 7 (0.52 g, 1.96 mmol), 4-chloro-1phenylbutan-1-one 8d (0.30 mL, 1.87 mmol), and sodium bicarbonate (0.19 g, 2.24 mmol) with water:2-butanone (18 mL, 1:5) to produce pure 9d (0.18 g, 0.43 mmol, 23% yield) as a colorless oil. 1 1-(4-Fluorophenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-one (9e). Method A: 7 (0.39 g, 1.44 mmol), 4-chloro-1-(4-fluorophenyl)butan-1-one 8e (0.28 g, 1.37 mmol), and sodium bicarbonate (0.14 g, 1.64 mmol) with water (3 mL) and 2-butanone (15 mL) to produce 9e (0.17 g, 0.40 mmol, 29% yield) as a colorless oil. 1 1-(4-Chlorophenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-one (9f). Method A: 7 (0.63 g, 2.34 mmol), 4-chloro-1-(4-chlorophenyl)butan-1-one 8f (0.48 g, 2.23 mmol), and sodium bicarbonate (0.23 g, 2.68 mmol) with water:2-butanone (18 mL, 1:5) to produce pure 9f (0.39 g, 0.88 mmol, 39% yield) as a colorless oil. 1 1-(4-Bromophenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-one (9g). Method A: 7 (0.44 g, 1.64 mmol), 1-(4bromophenyl)-4-chlorobutan-1-one (8g) (0.41 g, 1.56 mmol), and sodium bicarbonate (0.16 g, 1.88 mmol) with water (3 mL) and 2butanone (15 mL) to produce pure 9g (0.25 g, 0.50 mmol, 32% yield) as a colorless oil. 1 1-(4-Methoxyphenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-one (9h). Method A: 7 (0.49 g, 1.83 mmol), 4-chloro-1-(4-methoxyphenyl)butan-1-one (8h) (0.37 g, 1.74 mmol), and sodium bicarbonate (0.18 g, 2.09 mmol) with water (3 mL) and 2butanone (15 mL) to produce pure 9h (0.28 g, 0.64 mmol, 36% yield) as a colorless oil. 1 1-(4-(tert-Butyl)phenyl)-5-(4-(hydroxydiphenylmethyl)piperidin-1-yl)pentan-1-one (9j). Method A: 7 (0.54 g, 2.04 mmol), 1-(4-(tert-butyl)phenyl)-5-chloropentan-1-one (8j) (0.49 g, 1.94 mmol), and sodium bicarbonate (0.20 g, 2.33 mmol) with water:2-butanone (18 mL, 1:5) to produce pure 9j (0.60 g, 1.24 mmol, 64% yield) as a colorless oil. 1 1-(4-(tert-Butyl)phenyl)-3-(4-(hydroxydiphenylmethyl)piperidin-1-yl)propan-1-one (9k). Method A: 7 (0.54 g, 2.03 mmol), 1-(4-(tert-butyl)phenyl)-3-chloropropan-1-one (8k) (0.44 g, 1.94 mmol), and sodium bicarbonate (0.20 g, 2.32 mmol) with water:2-butanone (18 mL, 1:5) to produce pure 9k (0.84 g, 1.84 mmol, 95% yield) as a colorless oil. 1 13 1-(4-(tert-Butyl)phenyl)-2-(4-(hydroxydiphenylmethyl)piperidin-1-yl)ethanone (9l). Method A: 7 (0.40 g, 1.49 mmol), 1-(4-(tert-butyl)phenyl)-2-chloroethanone (8l) (0.30 g, 1.43 mmol), and sodium bicarbonate (0.14 g, 1.71 mmol) with water (3 mL) and 2butanone (15 mL) to produce pure 9l (0.45 g, 1.02 mmol, 72% yield) as a colorless oil. 1 33 (s, 9H) .). 13 (4-(tert-Butyl)phenyl)(4-(hydroxydiphenylmethyl)piperidin-1-yl)methanone (9m). To a vial was added the 7 (0.23 g, 0.87 mmol), acetonitrile (3 mL), and triethylamine (0.18 mL, 1.30 mmol). The 4-(tert-butyl)benzoyl chloride (8m) (0.17 mL, 0.95 mmol) was added and the reaction stirred at 70°C for 6 h and was then allowed to cool to rt and was diluted with EtOAc (15 mL) then washed with saturated NaHCO 3 (15 mL 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1yl)butyl)phenyl)-2-methyl propanoic Acid (1p). To a vial was added the 1o (0.094 g, 0.18 mmol) and THF (3 mL) to form a solution. The LiOH (0.022 g, 0.91 mmol) was dissolved in water (3 mL) and then added to the reaction and stirred at rt for 18 h. The reaction was acidified with 1.0 M HCl in water to pH 3. The aqueous layer was extracted with CH 2 Cl 2 (3 × 5 mL), and organic layers were combined and concentrated. The residue was purified by reverse-phase MPLC (10−100% CH 3 CN:water) to produce 2-(4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid 1p (0.038 g, 0.075 mmol, 41% yield). 1 (1-(4-(4-( t e r t-Butyl)phenyl)buty l)piperidin-4-yl)diphenylmethanol (2a). To a vial was added the 7 (0.15 g, 0.57 mmol), 1-(tert-butyl)-4-(4-chlorobutyl)benzene (10a) (0.15 g, 0.69 mmol), and potassium carbonate (0.47 g, 3.43 mmol) in acetonitrile (5 mL). The reaction stirred overnight at 85°C and for 18 h and was then cooled to rt and filtered. The filtrate was then diluted with brine and extracted with EtOAc (3 × 15 mL). The organic layers were combined, dried with MgSO 4 , filtered, and purified by reverse-phase MPLC (10−100% CH 3 CN:water) to produce pure 2a (0.18 g, 0.40 mmol, 69% yield) as an oil. 1 (1-(4-(tert-Butyl)phenethyl)piperidin-4-yl)diphenylmethanol (2c). Same procedure as 2a using 7 (0.15 g, 0.56 mmol), 1-(tert-butyl)-4-(2-chloroethyl)benzene (10c) (0.11 g, 0.56 mmol), and potassium carbonate (0.47 g, 3.37 mmol) in acetonitrile (5 mL 4-(4-Benzylpiperidin-1-yl)-1-(4-(tert-butyl)phenyl)butan-1-ol (2e).
Step 1: To a vial was added 12 (0.40 g, 1.21 mmol) and dry CH 2 Cl 2 (15 mL). The methanesulfonyl chloride (0.024 g, 0.35 g, 1.82 mmol) and triethylamine (0.51 mL, 3.64 mmol) were each added to the vial and the reaction stirred at rt for 16 h. The reaction was then diluted with CH 2 Cl 2 (15 mL) and washed with 1% w/v sulfuric acid in water (3 × 25 mL), saturated NaHCO 3 (25 mL), and brine (25 mL). The organic layer was dried with MgSO 4 , filtered, and concentrated to produce 3-(4-(hydroxy diphenylmethyl)piperidin-1-yl)propyl-4-methylbenzenesulfonate (0.19 g, 0.40 mmol, 33% yield), of which a portion was carried into step 2. 1 Step 2: To a vial was added the 3-(4-(hydroxydiphenyl methyl)piperidin-1-yl)propyl-4-methylbenzenesulfonate (0.088 g, 0.18 mmol), 4-(tert-butyl) aniline (0.035 mL, 0.22 mmol), and triethylamine (0.038 mL, 0.28 mmol) with acetonitrile (3 mL). The reaction began to stir at 85°C for 18 h and was then cooled to rt and diluted with saturated NaHCO 3 (10 mL) then extracted with EtOAc (2 × 15 mL). The organic layers were combined and concentrated then purified by reverse-phase MPLC (10−100% CH 3 CN:water) to produce pure 2e (0.038 g, 0.083 mmol, 45% yield). 1 (1-(3-(4-(tert-Butyl)phenoxy)propyl)piperidin-4-yl)diphenylmethanol (2f). To a vial was added the 3-(4-(hydroxydiphenyl methyl)piperidin-1-yl)propyl 4-methylbenzenesulfonate (0.11 g, 0.22 mmol) (from 2e step 1), 4-(tert-butyl)phenol (0.039 g, 0.26 mmol), and triethylamine (0.046 mL, 0.33 mmol) with acetonitrile (3 mL). The reaction began to stir at 85°C for 18 h and was then cooled to rt and diluted with saturated NaHCO 3 (10 mL) then extracted with EtOAc (2 × 15 mL). The organic layers were combined and concentrated then purified by reverse-phase MPLC GeneChip. The manufacturer's recommendations for the processing of prokaryotic arrays were then followed (Affymetrix; Santa Clara, CA). This was done in biological replicates a minimum of two times. In the data analysis, the control poly(A) cDNA signal intensity or the signals from the entire GeneChip were used to normalize each of the RNA species. These were then averaged with GeneSpring 7.2 software (Agilent Technologies, Redwood City, CA). Those isolates designated as differentially expressed were defined as the RNA species, which had at least a 2-fold difference in signal compared to the mock-treated sample (t-test, P = 0.05).
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Docking Studies. Using the Surflex module of the SYBYL 8.0 software package (Certara, St Louis, Mo), the receptor proteins (PDB IDs 2XCS, 2XCT and 3U2K) were prepared by removing the bound solved ligand then defining a pocket as a 20 Å sphere around the original ligand site. The corresponding terfenadine-based ligands were then docked into the original ligand site. The compounds were sketched and protonated in SYBYL, and Gasteiger−Marsili charges were assigned. Default Surflex settings were utilized, and the generated 30 docking poses per compound were visually inspected. The best pose was selected on the basis of Combined CScore (ChemScore, G_Score, D_Score, and PMF_Score) from the SYBYL software.
hERG Inhibition Assay. This assay was performed off-site at Eurofins Panlabs (Taiwan) and was adapted from a previous procedure. 59 Human recombinant potassium channel hERG is expressed in human HEK-293 cells in HEPES buffer at pH 7.4, 0.1% BSA, 5 mM KCl, 0.8 mM MgCl 2 , 130 mM NaCl, 1 mM EGTA, and 10 mM glucose. A 10 μg aliquot was incubated with [ 3 H] Astemizole, and either compound 4g or 6 in assay buffer containing 1% DMSO with 10 increasing doses (0.3 nM to 10 μM). Binding was terminated by filtration onto glass filters, followed by three washes with assay buffer. Radioactivity was determined by scintillation counting on each filter, and specifically bound [ 3 H] astemizole was determined. A dose−response curve was generated to provide the K i and IC 50 for the two compounds tested. 
